REG - Oxford Biomedica PLC - Block listing Application

Oxford BioMedicaAnnouncement

22/01/2020 12:15

RNS Number : 6110A
Oxford Biomedica PLC
22 January 2020
 


 
 
 
Oxford Biomedica
Block listing Application
 
Oxford, UK - 22 January 2020: Oxford Biomedica plc ("OXB" or "the Group") (LSE: OXB), announces that applications have been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for a block listing of 400,000 ordinary shares of 50 pence each (the "Ordinary Shares").
 
The Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the following schemes:
 
·      OXB Employee Share Option Scheme (ESOS) (200,000 Ordinary Shares); and
·      OXB Save as You Earn (SAYE) Share Option Scheme (200,000 Ordinary Shares).
 
It is expected that admission of the Ordinary Shares will become effective on 28 January 2020. The Ordinary Shares will rank pari passu in all respects with the Group's existing ordinary shares in issue.
 
 
-Ends-
 



For further information, please contact:


 




 
Oxford Biomedica plc:
Natalie Walter, Company Secretary


 
Tel: +44 (0)1865 783 000



 
 
About Oxford Biomedica
 
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 480 people. Further information is available at www.oxb.com
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSBDGDBCGDDGGD